Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting in Palo Alto (17 mi)

Overseen byRebecca Aft, M.D., Ph.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Washington University School of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.

Research Team

Rebecca Aft, M.D., Ph.D.

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

Inclusion Criteria

Recently diagnosed with clinical stage II, III, or IV breast cancer

Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have already completed neoadjuvant systemic therapy are also eligible

Must be >= 18 years of age

See 3 more

Treatment Details

Interventions

Bone marrow biopsy (Procedure)
Breast tissue collection (Procedure)
Neoadjuvant or Adjuvant Systemic Therapy (Chemotherapy)
Peripheral blood draw (Procedure)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Tissue, blood, and bone marrow (optional) collectionExperimental Treatment3 Interventions

* Undergo neoadjuvant systemic therapy * initial surgery for sentinel lymph node biopsy/portacath placement * definitive cancer surgery (if applicable) * when portacath is removed (1 year, if available) * if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis * Undergo Adjuvant Systemic Therapy * initial surgery for a sentinel lymph node biopsy/portacath placement * when portacath is removed (1 year, if available) * If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis. * Undergone neoadjuvant systemic therapy * during definitive cancer surgery/portacath removal (if available) * if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis